0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Pioglitazone vs Glimepiride in the PERISCOPE Trial—Reply

Steven E. Nissen, MD; Stephen J. Nicholls, MD, PhD; Kathy Wolski, MPH
JAMA. 2008;300(7):787-788. doi:10.1001/jama.300.7.788-a.
Text Size: A A A
Published online

Extract

In Reply: Dr Fresco comments that the primary end point showed progression in the pioglitazone treatment group for patients not treated with statins. We disagree and recommend caution in interpretation of subgroup data. In the pioglitazone group, the 95% CI for the primary end point for the subgroup not receiving statins ranged from −0.45 to 2.29. The lower limit of the CI being less than 0 was consistent with the overall study results. In any clinical trial, results in subgroups are considered hypothesis-generating at best because when multiple groups are assessed, the likelihood of an apparent difference occurring by chance alone is substantial. In this case, we think that even more caution is required. There were only 29 patients in the glimepiride group who did not receive statins and only 25 in the pioglitazone group. We did not stratify for statin use because we expected nearly all patients to receive statins and knew that many different agents would be used, precluding any reasonable stratification approach.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

August 20, 2008
Claudio Fresco, MD
JAMA. 2008;300(7):787-788. doi:10.1001/jama.300.7.787-a.
August 20, 2003
Lisa A. Honkanen, MD
JAMA. 2003;290(7):883. doi:10.1001/jama.290.7.883-a.
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();